Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease
Anita G. Koshy(Beth Israel Deaconess Medical Center), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Corey Cutler(Harvard University), Vincent T. Ho(Dana-Farber Cancer Institute), Mahasweta Gooptu(Harvard University), Haesook T. Kim(Dana-Farber Cancer Institute), David Avigan(Beth Israel Deaconess Medical Center), Joseph H. Antin(Dana-Farber Cancer Institute), Sarah Nikiforow(Otsuka (Japan)), Hassan El Banna(Dana-Farber Cancer Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Pavania Elavalakanar(Beth Israel Deaconess Medical Center), Emma Logan(Beth Israel Deaconess Medical Center), Giulia Cheloni(Beth Israel Deaconess Medical Center), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Poorva Bindal(Beth Israel Deaconess Medical Center), Susan Stephenson(Harvard University), Jessica J. Liegel(Beth Israel Deaconess Medical Center)
Cited by 3
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k